RecruitingNot ApplicableNCT04253301

Feasibility of the InnoVein Valve and Delivery System for Chronic Venous Insufficiency


Sponsor

InnoVein

Enrollment

5 participants

Start Date

Jan 15, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

This objective of this feasibility study is to evaluate the safety of the InnoVein Valve and Delivery System for treatment of chronic venous insufficiency.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Willing and able to provide written Informed Consent
  • Diagnosis of symptomatic non-obstructive chronic valvular insufficiency of the femoral vein
  • Willing and medically able to receive intraprocedural and post-procedural anticoagulation medication
  • Life expectancy >1yr
  • Reflux time >1s in the superficial femoral and/or popliteal vein

Exclusion Criteria8

  • Any prior deep vein intervention within 6 months prior to the Index Procedure
  • History of 2+ DVTs
  • Inadequate inflow to the femoral vein or inadequate outflow through the femoral vein, iliac vein, or IVC
  • Current IVC Placement
  • History of pulmonary embolism within 6 months
  • Conditions that increase the risk of device thrombosis or patient bleeding
  • Any planned surgical or interventional procedure within 30 days prior to or after the Index Procedure
  • Investigator or sponsor believes the subject would not benefit, would not be appropriate, be unable to follow-up, or be at high risk for non-compliance with the protocol

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEInnoVein Valve Treatment

Subjects will have the InnoVein Valve implanted


Locations(3)

Hollywood Private Hospital

Nedlands, Western Australia, Australia

Sir Charles Gairdner Hospital

Nedlands, Western Australia, Australia

Flinders

Adelaide, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04253301


Related Trials